公开(公告)号：EP2068823A2

公开(公告)日：2009-06-17

申请号：EP07861359.3

申请日：2007-09-24

申请人： Schering Corporation

发明人： MONTEITH, David ,  VELTRI, Enrico, P. ,  DUGGIRALA, Srinivas ,  FALVO, Michael, Angelo ,  ERBEY II, John, R. ,  FENG, Kung-i ,  PAVLOVSKY, Anastasia ,  CHAWDRY, Suliman

IPC分类号： A61K9/00 ,  A61K9/19 ,  A61K31/4402 ,  A61K31/5377 ,  A61P7/02

CPC分类号： A61K31/4402 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/2095 ,  A61K31/5377

摘要： Disclosed is a lyophilized rapidly disintegrating solid dosage form, one embodiment of which comprises a thrombin receptor antagonist such as, formula (A), or a pharmaceutically acceptable salt or hydrate thereof, a polymer such as gelatin, and a matrix forming agent such as mannitol. Systems for effectively buffering the pre-lyophilized suspension are taught, along with methods of treating patients at risk for acute coronary syndrome by administering such a rapidly disintegrating solid dosage form.

公开(公告)号：EP1919478A2

公开(公告)日：2008-05-14

申请号：EP06760571.7

申请日：2006-05-31

申请人： Schering Corporation

发明人： MALCOLM, Bruce, A. ,  BRADLEY, Prudence, K. ,  PAVLOVSKY, Anastasia ,  CHO, Wing-Kee, Philip ,  QIU, Zhihui

IPC分类号： A61K31/454

CPC分类号： A61K38/12 ,  A61K31/454 ,  A61K31/4709 ,  A61K38/05 ,  A61K38/06 ,  A61K38/08 ,  A61K47/10 ,  A61K2300/00

摘要： Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

公开(公告)号：EP1701953A1

公开(公告)日：2006-09-20

申请号：EP05705212.8

申请日：2005-01-07

申请人： SCHERING CORPORATION

发明人： THIRUVENGADAM, Tiruvettipuram, K. ,  WU, Wenxue ,  WANG, Tao ,  CHIU, John, S. ,  BOGDANOWICH-KNIPP, Susan ,  PAVLOVSKY, Anastasia ,  GREENLEE, William, J. ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu ,  CHACKALAMANNIL, Samuel

IPC分类号： C07D405/06 ,  C07D307/00 ,  C07D213/00

CPC分类号： C07D417/14 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/06 ,  C07D405/14 ,  C07D413/14

摘要： A crystalline polymorph of a bislulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimtery profile substantially the same as that shown in FIG. 3, and is represented by the formula for Compound 2: Chemical formula should be inserted here as it appears on the abstract in paper form. and processes for preparing Compound 2 are disclosed. Pharmaceutical compositions comprising the polymorph of the bisulfate salt and at least one excipient or carrier, and methods of using the polymorph of Compound 2 to treat a variety of physiological disorders, such as thrombosis, are also disclosed.